Previous close | 0.8010 |
Open | 0.8015 |
Bid | 0.8236 x 300 |
Ask | 0.8676 x 100 |
Day's range | 0.8015 - 0.8977 |
52-week range | 0.5390 - 1.3800 |
Volume | |
Avg. volume | 393,619 |
Market cap | 62.321M |
Beta (5Y monthly) | 2.34 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.3600 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024. Please contact your Piper Sandler representative to sched
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH). “Dosing the first subjects in our Phase 2a HERALD study is an important mile
Is it a good or bad thing when a stock experiences a golden cross technical event?